In this deep dive into the importance of subtyping in PD, leading authorities Chin-Hsien Lin, MD, PhD, National Taiwan University; Alberto Espay, MD, FAAN, University of Cincinnati, Etienne Hirsch, PhD, Inserm, Sorbonne Université; and Alice Chen-Plotkin, MD, University of Pennsylvania, talk on the limitations of clinical subtyping and why a one-size-fits-all approach to clinical trials is unlikely to succeed, as well as how we can define new subpopulations and the practical considerations.
